Anxiety Disorders (Adult) Research Study
|
Association Between Adenosine Receptor Gene Polymorphisms and Physiological Responses to Caffeine in Subjects with Panic Disorder and Healthy Controls
|
Caffeine, the most widely used psychoactive drug in the world, exerts its behavioral effects by antagonizing adenosine receptors (AR). Four different human AR subtypes have been found and there is evidence that the stimulatory effect of caffeine is mainly caused by an inhibition of transmission via adenosine A(2a) receptors. A significant association has been found in healthy infrequent caffeine users between caffeine-induced anxiety and two linked polymorphisms on the A(2a) receptor gene Studies have demonstrated that individuals with panic disorder have a higher anxiety reaction to caffeine than healthy controls. Family and twin studies have shown that genetic factors may increase vulnerability to panic disorder. In one study a systematic mutation screening and association study of the A(1) and A(2a) adenosine receptor genes in panic disorder showed a significant association between the 1976T allele and 1976T/T genotype of the A(2a) receptor gene and panic disorder. As the 1976T/T genotype polymorphism of the A(2a) receptor gene has been associated with both increased caffeine-induced anxiety in healthy controls, and has been associated with increased vulnerability to panic disorder, we wish to study whether the 1976T/T genotype in panic disorder patients is associated with increased caffeine-induced anxiety. This study will study subjects with panic disorder (both current and remitted) and healthy controls. After the initial screening process which includes a psychiatric and medical evaluation, individuals participating in this study will have two 4 hour research sessions. In one session individuals will be given 480 mg of caffeine (comparable to 4 to 5 cups of coffee) in capsule form and in the other session placebo (sugar pill). During the sessions participants will be rated in terms of mood and anxiety in order to assess their reaction to caffeine and placebo. Participants will also be administered neuropsychological tests during the sessions. Subjects will be compensated for particpating in this study.
To find out if you qualify or for more information, please call (301) 496-5645 or email us at nimhcore@mail.nih.gov.
|
|
 
|
|
|
|
Protocol Information |
|
| |
|
|
Anxiety Disorders (Adult) Research Study
|
Brain Imaging in Panic Disorder
|
If you are currently experiencing panic attacks, you may be eligible to participate in a brain imaging study. This study is being conducted to try to better understand panic disorder. These are outpatient studies requiring three to four visits. Subjects should be 18 - 60 years of age, currently experiencing panic attacks or never have experienced panic attacks or depression in the past and are otherwise medically healthy and not taking any medication. These studies include medical and psychiatric evaluations, and brain imaging. Compensation is provided. To find out if you qualify please call: 301-496-4541.
To find out if you qualify or for more information, please call (301) 496-5645 or email us at nimhcore@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Anxiety Disorders (Adult) Research Study
|
Effects of D-Cycloserine on Treatment in Social Anxiety
|
This study examines whether an antibiotic, d-cycloserine (DCS), boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety. CBT has been shown to be effective for the treatment of social anxiety in children and adults, but even after treatment, approximately 40% may remain diagnosable.
All participants will receive 12 weekly CBT sessions. In addition to receiving the CBT, participants will be randomly assigned (similar to a coin toss) to receive either DCS or a placebo (sugar pill). The pill will be taken 1-2 hours prior to each of the 12 CBT sessions. The pill is taken only on the 12 therapy days. If you are ages 7-55 with a social phobia, you may be eligible for the study.
To find out if you qualify or for more information, please call (301) 496-5645 or email us at nimhcore@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Anxiety Disorders (Adult) Research Study
|
Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors with [18F]SPA-RQ
|
The involvement of Substance P (SP) in depression and anxiety has been credibly demonstrated in a recent clinical trial. Although the precise physiological activation mechanism of the SP system is not yet known, the likelihood of exaggerated SP pathway activity in the pathogenesis of anxiety is supported in numerous animal studies that illustrate the anxiogenic, and anxiolytic effects of SP and SP antagonists (SPAs), respectively. Studies have further shown that SP release occurs in response to noxious, or aversive stimulation. SP stimulates NK1 receptors that then undergo endocytosis (i.e., internalization) resulting in a decrease in number of NK1 receptors on the cell surface. NK1 receptor quantification before, and after an aversive event, provides a dynamic measurement of SP neurotransmission.
In this protocol, we will use a new PET ligand that has demonstrated ability to serve as an NK1 receptor antagonist, [18F]SPA-RQ ( [18F]-labeled Substance P Antagonist Receptor Quantifier). Using this tracer, we will: 1.) quantify NK1 binding parameters and determine the reliability and reproducibility of these measures in 10 healthy controls, 2.) we will look for regional differences in NK1 receptor binding in 20 patients with panic disorder (PD) versus 20 normal controls, and 3.) we will perform a single- blind, placebo-controlled study to evaluate NK1 receptor binding in PD patients and controls following either room air or 7.5% CO2 inhalation. The majority of PD patients, but not controls, are expected to experience a panic attack (aversive event) following CO2 inhalation. Comparison of pre-panic and post-panic NK1 receptor binding in PD patients will provide an estimate of SP release. The goal of the present study is to demonstrate the involvement of SP in panic disorder, and thereby, further our understanding of its role in the psychopathology of this illness.
To find out if you qualify or for more information, please call (301) 496-5645 or email us at nimhcore@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Anxiety Disorders (Adult) Research Study
|
Generalized Anxiety Disorder and Social Anxiety Disorder: Their impact on the processing of social emotional information and instrumental learning
|
If you consider yourself to experience more anxiety or are shyer than those around you or have been diagnosed with generalized anxiety disorder or social anxiety disorder, you may be able to participate in this study examining how the brain responds to and analyzes emotional events. Our goal is to understand what is special about the brain response to emotional events in people with anxiety disorders. We assess brain responses with both computer tasks and brain imaging (functional Magnetic Resonance Imaging; fMRI).
Healthy volunteers who have no history of psychiatric or major medical illness will also be enrolled in this study.
To find out if you qualify or for more information, please call (301) 496-5645 or email us at nimhcore@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Anxiety Disorders (Adult) Research Study
|
NIMH FAMILY STUDY OF HEALTH AND BEHAVIOR
|
The major goal of this study is to examine how mood disorders, anxiety disorders and migraine run in families. We study both genetic and environmental factors that may contribute to these conditions. We recruit people ages 21 and over with depression, manic-depression, social phobia, panic, generalized anxiety, migraine and people without any of these problems. Participants are interviewed about medical and mental symptoms and problems, their health behavior, social factors and a variety of other measures related to their health and behavior. Family members ages 8 and over will also be asked to participate. Some families will be invited to participate in further studies of biological and genetic factors.
To find out if you qualify or for more information, please call 1-877-250-1560 or email at familystudy@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Anxiety Disorders (Adult) Research Study
|
Predictability and Aversive Expectancies in Anxiety Disorders
|
If you consider yourself to experience more anxiety than those around you or have been diagnosed with generalized anxiety disorder, social anxiety disorder, panic disorder, or specific phobia, you may be able to participate in this study examining changes in the body and brain that occur during fear and fear learning. Basic research has identified biological processes that play a key role in fear and anxiety. The present study examines such processes across those with and without elevated levels of anxiety to better understand the biological basis of anxiety disorders. More specifically, we will be assessing changes in heart rate (EKG), muscle activity (EMG), sweat responses (SCR) and respiration that occur during exposure to mildly unpleasant events. Healthy volunteers who have no history of psychiatric or major medical illness will also be enrolled in this study.
To find out if you qualify or for more information, please call (301) 496-5645 or email us at nimhcore@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Bipolar Disorder (Adult) Research Study
|
Antidepressant (Rapid) Effects of Ketamine
|
If you (or someone you know) have been diagnosed with bipolar disorder, you may be able to participate in a trial designed to understand the causes of depression and rapid antidepressant response. Specifically, we are testing whether ketamine, a drug that affects glutamate in the brain will improve symptoms of depression within a matter of hours.
If you are 18-60 years of age and have been diagnosed with bipolar disorder and previously failed to respond to treatment, you may be eligible for an inpatient trial designed to bring about a rapid antidepressant effect.
After completion of the study the participant is transitioned back to a clinician in the community. In addition, all research participation is without cost and we will cover all transportation costs from anywhere in the United States. Compensation is provided for study procedures.
To find out if you qualify or for more information, please call 1-877-MIND-NIH (1-877-646-3644) or email us at moodresearch@mail.nih.gov .
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Bipolar Disorder (Adult) Research Study
|
Antidepressant Effects of Ceftriaxone in Bipolar Depression
|
If you (or someone you know) have been diagnosed with bipolar disorder (manic depression), you may be able to participate in a trial designed to understand the causes of depression and antidepressant response. Specifically, we are testing whether the antibiotic ceftriaxone, would improve symptoms of depression.
If you are 18-65 years of age and have been diagnosed with bipolar disorder and are currently depressed, you may be eligible for an inpatient trial.
After completion of the study, the participant is transitioned back to a clinician in the community. In addition, all research participation is without cost and we will cover all transportation costs from anywhere in the United States. Compensation is provided for study procedures.
To find out if you qualify or for more information, please call 1-877-MIND-NIH (1-877-646-3644) or email us at moodresearch@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Bipolar Disorder (Adult) Research Study
|
Bipolar Disorder Genetics: A Collaborative Study
|
If you have been diagnosed with bipolar disorder (BP) you may be eligible to participate in a research study at the NIH clinical Center. The purpose of this study is to identify genes that may contribute to the development of bipolar disorder (manic depression), and related conditions. Bipolar disorder is a common and potentially life-threatening mood disorder. The tendency to develop bipolar disorder can be inherited, but this is poorly understood and probably involves multiple genes. This study will use genetic markers to map and identify genes that contribute to bipolar disorder.
Families and individuals who have the disorder are asked to contribute personal information and a blood sample to an anonymous national database. This information will aid scientists around the world who are working together to develop better treatments for this serious mood disorder.
To find out if you qualify or for more information, please call 1-866-644-4363 or email us at kazubad@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Bipolar Disorder (Adult) Research Study
|
Brain Imaging in Bipolar Disorder
|
If you are currently depressed, you may be eligible to participate in a brain imaging study. This study is being conducted to try to better understand depression in bipolar disorder also know as manic-depressive illness. These are outpatient studies requiring three to four visits. Subjects should be 18 - 60 years of age, currently depressed or never have experienced depression in the past and are otherwise medically healthy and not taking any medication. These studies include medical and psychiatric evaluations, and brain imaging. Compensation is provided.
To find out if you qualify or for more information, please call (301) 594-3186 or email us at drevetsm@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Bipolar Disorder (Adult) Research Study
|
NIMH FAMILY STUDY OF HEALTH AND BEHAVIOR
|
The major goal of this study is to examine how mood disorders, anxiety disorders and migraine run in families. We study both genetic and environmental factors that may contribute to these conditions. We recruit people ages 21 and over with depression, manic-depression, social phobia, panic, generalized anxiety, migraine and people without any of these problems. Participants are interviewed about medical and mental symptoms and problems, their health behavior, social factors and a variety of other measures related to their health and behavior. Family members ages 8 and over will also be asked to participate. Some families will be invited to participate in further studies of biological and genetic factors.
To find out if you qualify or for more information, please call 1-877-250-1560 or email at familystudy@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Bipolar Disorder (Adult) Research Study
|
Riluzole to treat Depression in Bipolar Disorder
|
If you (or someone you know) have been diagnosed with bipolar depression or manic-depressive illness, you may be able to participate in our clinical trial designed to decrease symptoms of depression and understand the causes of depression. Specifically, we are testing whether riluzole (FDA approved for ALS also known as Lou Gehrig's disease) a drug that affects glutamate in the brain will improve symptoms of depression. We are also conducting neuropsychological testing in this study.
If you are 18-70 years of age and have been diagnosed with bipolar depression, you may be eligible for an outpatient or inpatient clinical trial of riluzole in bipolar depression.
After completion of the study the participant is transitioned back to a clinician in the community. In addition, all research participation is without cost and we will cover all transportation costs from anywhere in the United States. Compensation is provided for participation in neuropsychological exams.
To find out if you qualify or for more information, please call 1-877-MIND-NIH (1-877-646-3644) or email us at moodresearch@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Depression (Adult) Research Study
|
Brain Imaging in Depression
|
If you are currently depressed, you may be eligible to participate in a brain imaging study. This study is being conducted to try to better understand depression in major depressive disorder and bipolar disorder. These are outpatient studies requiring three to four visits. Subjects should be 18 - 60 years of age, currently depressed or have never experienced depression in the past and are otherwise medically healthy and not taking any medication. These studies include medical and psychiatric evaluations, and brain imaging. Compensation is provided.
To find out if you qualify or for more information, please call (301) 594-3186 or email us at drevetsm@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Depression (Adult) Research Study
|
Depression & NR2B
|
If you (or someone you know) have been diagnosed with major depression, you may be able to participate in our clinical trial designed to decrease symptoms of depression and understand the causes of depression. Specifically, we are testing whether a selective NR2B antagonist, MK-0657, compared with placebo will be effective in improving overall depressive symptomatology in patients with treatment-resistant major depression.
If you are 18-55 years of age and have been diagnosed with major depression (unipolar) and have previously failed to respond to an antidepressant, you may be eligible for this inpatient clinical trial.
After completion of the study the participant is transitioned back to a clinician in the community. In addition, all research participation is without cost and we will cover all transportation costs from anywhere in the United States.
To find out if you qualify or for more information, please call 1-877-MIND-NIH (1-877-646-3644) or email us at moodresearch@mail.nih.gov .
|
|
|
|
|
|
Disease and Treatment Information |
|
| |
|
|
Depression (Adult) Research Study
|
NIMH FAMILY STUDY OF HEALTH AND BEHAVIOR
|
The major goal of this study is to examine how mood disorders, anxiety disorders and migraine run in families. We study both genetic and environmental factors that may contribute to these conditions. We recruit people ages 21 and over with depression, manic-depression, social phobia, panic, generalized anxiety, migraine and people without any of these problems. Participants are interviewed about medical and mental symptoms and problems, their health behavior, social factors and a variety of other measures related to their health and behavior. Family members ages 8 and over will also be asked to participate. Some families will be invited to participate in further studies of biological and genetic factors.
To find out if you qualify or for more information, please call 1-877-250-1560 or email at familystudy@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Depression (Adult) Research Study
|
Pramipexole and Escitalopram to Treat Major Depressive Disorder
|
If you (or someone you know) have been diagnosed with major depression, you may be able to participate in our clinical trial designed to decrease symptoms of depression and understand the causes of depression. Specifically, we are testing whether the combination of pramipexole (FDA approved for Parkinson's disease) with lexapro (a first line antidepressant) will improve symptoms of depression more than either drug alone.
If you are 18-65 years of age and have been diagnosed with major depression (unipolar) and have previously failed to respond to an antidepressant, you may be eligible for an outpatient or inpatient clinical trial of the combination of pramipexole with lexapro in major depression.
After completion of the study the participant is transitioned back to a clinician in the community. In addition, all research participation is without cost and we will cover all transportation costs from anywhere in the United States.
To find out if you qualify or for more information, please call 1-877-MIND-NIH (1-877-646-3644) or email us at moodresearch@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Depression (Adult) Research Study
|
Rapid Antidepressant Effects of Ketamine
|
If you (or someone you know) have been diagnosed with major depression, you may be able to participate in a trial designed to understand the causes of depression and rapid antidepressant response. Specifically, we are testing whether ketamine, a drug that affects glutamate in the brain will improve symptoms of depression within a matter of hours.
If you are 18-60 years of age and have been diagnosed with major depression (unipolar) and previously failed to respond to treatment, you may be eligible for an inpatient trial designed to bring about a rapid antidepressant effect.
After completion of the study the participant is transitioned back to a clinician in the community. In addition, all research participation is without cost and we will cover all transportation costs from anywhere in the United States. Compensation is provided for study procedures.
To find out if you qualify or for more information, please call 1-877-MIND-NIH (1-877-646-3644) or email us at moodresearch@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Depression (Adult) Research Study
|
Yohimbine to Induce Rapid Antidepressant Effects
|
If you (or someone you know) have been diagnosed with major depression, you may be able to participate in a trial designed to understand the causes of depression and rapid antidepressant response. Specifically, we are testing whether yohimbine when given at a specific time during the sleep cycle will improve symptoms of depression within a matter of hours.
If you are 18-60 years of age and have been diagnosed with major depression (unipolar), you may be eligible for an inpatient trial designed to bring about a rapid antidepressant effect.
After completion of the study the participant is transitioned back to a clinician in the community. In addition, all research participation is without cost and we will cover all transportation costs from anywhere in the United States. Compensation is provided for study procedures.
To find out if you qualify or for more information, please call 1-877 MIND NIH (1-877-646-3644) or email us at moodresearch@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Obsessive-Compulsive Disorder (Adult) Research Study
|
Genetics of Obsessive-Compulsive Research Study
|
If you have been diagnosed with obsessive-compulsive disorder (OCD) you and your family may be able to participate in an OCD research study. The purpose of this study is to identify genes that affect susceptibility to OCD. By identifying genes that increase or decrease the risk of OCD, researchers can better understand how the condition develops and ultimately improve treatment for people with OCD. OCD is a severe, familial condition that affects approximately 2% of the population. The way OCD is inherited is not clearly understood, but researchers believe it is complex and involves multiple genes. This study will detect and localize genes that increase or decrease susceptibility to OCD. The data collected from this study will be combined with data from other research studies to determine gene linkage and association.
Eligible volunteers will contribute in three ways: A confidential questionnaire packet, an interview and a sample of blood. Travel is not needed. You will receive monetary compensation for participating in this study.
To find out if you qualify or for more information, please call 301-496-8977 or toll free at 1-866-644-4363,
or email us at kazubad@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Obsessive-Compulsive Disorder (Adult) Research Study
|
OCD Sibling Study (Adult)
|
We are examining the causes of Obsessive-Compulsive Disorder (OCD) by looking at the relationship between OCD, the brain, and genetic factors. We are enrolling sibling pairs (ages 18-55) where one sibling has the diagnosis of OCD and the other does not. Siblings must be full siblings (same mother and father).
The 1-day study involves a structured psychiatric interview, psychological testing, a Magnetic Resonance Imaging (MRI) scan, and a brief blood draw. Financial compensation and travel assistance is provided.
To find out if you qualify or for more information, please call 301-496-0851 or toll-free at 888-254-3823 or email us at sharpw@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Phantom Limb Pain Research Study
|
Test 1_5_09_1
|
Test
|
|
|
|
Post-Traumatic Stress Disorder (Adult) Research Study
|
Human Resilience & Posttraumatic Stress Disorder (PTSD)
|
Are you an adult trauma survivor? You may be eligible to participate in a study of brain changes and psychological characteristics of people who are resilient to trauma. It will examine and compare responses in three categories of subjects: 1) women who have been exposed to a significant traumatic event and suffer symptoms of post-traumatic stress disorder (PTSD) severe enough to interfere with their ability to function; 2) women who have been exposed to a significant traumatic event and do not suffer PTSD symptoms severe enough to interfere with their ability to function; and 3) women who have never been exposed to a significant traumatic event. Most people who are exposed to trauma recover well from the adversity. Some gain greater self-confidence of strengthening personal relationships. Others, however, develop PTSD and may have repeated thoughts, images, and dreams of the trauma; feel upset when reminded of the traumatic event; avoid places or people that remind them of the trauma; feel detached from others; have difficulty sleeping and concentrating; or startle easily. Understanding these differences may help lead to improved treatments.
To find out if you qualify or for more information, please call 1-866-627-6464 or email us at giesenh@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Schizophrenia (Adult) Research Study
|
A Study of Schizophrenia and the Brain: A Six-month Inpatient Evaluation Study
|
Have you been diagnosed with schizophrenia or schizoaffective disorder? Are you between 18 and 55 years of age? Would you be willing to live at the Clinical Center on the NIH campus for six months? If so, you may be eligible to participate in a study designed to understand the neurological basis of schizophrenia and to determine which symptoms are related to the illness and which are related to the medications used to treat the illness.
This six-month study has three phases: In the first phase you will participate in many comprehensive medical, neurological, cognitive, and psychiatric evaluations. In the second phase, the research phase, you will be tapered off of your medication for about 4 weeks. In the time that your medication is discontinued, research procedures will allow investigators to distinguish the effects of the illness on the brain without the interference of the medication's effects. In the third phase, you will have the opportunity to stabilize using the treatment selected to be most helpful to you.
To find out if you qualify or for more information, please call 301-435-8970 (1-888-674-6464) or email us at schizophrenia@mail.nih.gov.
If you are interested in inpatient studies of shorter duration that do not require that you stop taking medication, please ask about the Tolcapone and Modafinil studies of schizophrenia and short-term memory.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Schizophrenia (Adult) Research Study
|
Clinical Trial of Modafinil for Cognition in Schizophrenia
|
Are you having difficulty with your concentration? Are you between 18 and 50 years of age? If you have also received the diagnosis of schizophrenia or schizoaffective disorder, then you may be able to participate in a brief clinical trial assessing the effectiveness of a medication named modafinil on your ability to concentrate, remember, and solve problems. During the study, you will be asked to stay at the NIH Clinical Center so the effects of this medication can be carefully monitored. Modafinil will be administered along with the medication that you are currently taking. To enable us to examine how this medication affects your brain function and metabolism, you will be asked to undergo physical evaluations, no radioactive brain scans, and paper and pencil tests. This study also includes normal volunteers.
To find out if you qualify or for more information, please call 301-435-8970 (1-888-674-6464) or email us at schizophrenia@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Schizophrenia (Adult) Research Study
|
Clinical Trial of Tolcapone for Cognition in Schizophrenia
|
Are you having difficulty with your concentration? Are you between 18 and 50 years of age? If you have also received the diagnosis of schizophrenia or schizoaffective disorder, then you may be able to participate in a brief clinical trial assessing the effectiveness of a medication named tolcapone on your ability to concentrate, remember, and solve problems. During the study, you will be asked to stay at the NIH Clinical Center so the effects of this medication can be carefully monitored. Tolcapone will be administered along with the medication that you are currently taking. To enable us to examine how this medication affects your brain function and metabolism, you will be asked to undergo physical evaluations, no radioactive brain scans, and paper and pencil tests. This study also includes normal volunteers.
To find out if you qualify or for more information, please call 301-435-8970 (1-888-674-6464)or email us at schizophrenia@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Schizophrenia (Adult) Research Study
|
Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers with 1.5 Tesla MRI
|
If you have been diagnosed with schizophrenia or another neurological or neuropsychiatric disorder, you may be eligible to participate in this study. Its purpose is to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. This study will use magnetic resonance imaging (MRI) scans to identify abnormalities in neurophysiology, neurochemistry and neuroanatomy that characterize schizophrenia and other disorders. More specifically, we hope to clarify the neuronal changes that occur in localized regions of the brain which may result in widespread, devastating consequences.
Healthy volunteers who have no history of psychiatric or major medical illness will also be enrolled in this study.
To find out if you qualify or for more information, please call 301-435-8970 (1-888-674-6464) or email us at schizophrenia@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Schizophrenia (Adult) Research Study
|
Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers with 3.0 Tesla MRI and Magnetoencephalography
|
If you have been diagnosed with schizophrenia or another neurological or neuropsychiatric disorder, you may be eligible to participate in this study. Its purpose is to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. This study will use magnetic resonance imaging (MRI) scans to identify abnormalities in neurophysiology, neurochemistry and neuroanatomy that characterize schizophrenia and other disorders. More specifically, we hope to clarify the neuronal changes that occur in localized regions of the brain which may result in widespread, devastating consequences.
Healthy volunteers who have no history of psychiatric or major medical illness will also be enrolled in this study.
To find out if you qualify or for more information, please call 301-435-8970 (1-888-674-6464) or email us at schizophrenia@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Schizophrenia (Adult) Research Study
|
The NIMH Genetic Study of Schizophrenia
|
If you or someone in your family is 18 years old or older and has been diagnosed with schizophrenia or schizoaffective disorder (depressed type), you may be able to participate in a genetic study that looks for genes in families. In order for family members to participate, the person with schizophrenia must be willing and able to participate. Eligible family members participate in an interview and contribute a sample of blood for genetic analysis. If you have schizophrenia, and if possible, your sibling, you may qualify to participate in this study. There is no change in medication involved.
The study involves simple cognitive tests and some MRI scans (no radiation). All testing is completed free of charge and there is compensation for each family member's participation in the study. Travel and lodging assistance is also available.
Scientists believe that the identification of susceptibility genes is key to understanding the molecular pathways of this disease so that better treatments and preventive methods can be developed in the future.
To find out if you qualify or for more information, please call 301-435-8970 (1-888-674-6464) or email us at schizophrenia@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
Velocardiofacial Syndrome (VCFS) Research Study
|
Velocardiofacial syndrome (VCFS) and the Brain
|
Small deletion syndromes are caused by the loss of a stretch of genes from one of the two chromosomes they are located on during germ cell development. They offer a unique opportunity to study how relatively pronounced changes in the effects of relatively few genes lead to disturbances in brain function.
The most common such condition, Velocardiofacial syndrome, also known as 22q11.2 syndrome or DiGeorge syndrome, has been associated with many features such as a cleft palate, heart defects, and learning, speech and feeding problems. It is caused by the absence of a number of genes on chromosome 22.
We are recruiting participants with 22q11.2 syndrome to come to our main campus in Bethesda, MD, to participate in a study in which we will investigate the genetic makeup of their cells together with several studies of brain function with advanced research imaging. The goal of this study is to understand how the genes missing in 22q11.2 syndrome are related to the increased occurrence of psychiatric problems, such as psychosis. Participants must be 18-50 years of age, have some high school education and not currently be taking antipsychotic medication. Travel costs to Bethesda for participants and an accompanying person will be paid, and participants are reimbursed for their time in participating in the study. A blood draw is required. All research procedures have been designated as "minimal risk" procedures.
To find out if you qualify or for more information, please call (301) 496-5645 or email at nimhcore@mail.nih.gov.
|
|
|
|
|
|
Protocol Information |
|
| |
|
|
|
|
